TSS
IOVA icon

Two Sigma Securities’s Iovance Biotherapeutics IOVA Stock Holding History

Two Sigma Securities’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24,565
Closed -$86.2K – 2054
2026
Q1 		$86.2K Buy
24,565
+10,525
+75% +$33.7K 0.01% 1195
2025
Q4 		$38.3K Buy
+14,040
New +$32.5K 0.01% 1108
2025
Q3 		– Sell
-45,858
Closed -$78.9K – 1700
2025
Q2 		$78.9K Buy
+45,858
New +$114K 0.01% 1070
2024
Q3 		– Sell
-11,483
Closed -$92.1K – 3226
2024
Q2 		$92.1K Buy
+11,483
New +$123K ﹤0.01% 2497
2017
Q3 		– Sell
-13,763
Closed -$101K – 1061
2017
Q2 		$101K Buy
+13,763
New +$87.5K 0.02% 651

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Two Sigma Securities's IOVA Position: Q2 2026 in Review

Two Sigma Securities sold out of Iovance Biotherapeutics (IOVA) in Q2 2026, closing a stake of 24,565 shares — an estimated $86.2K sold.

Two Sigma Securities first reported a position in IOVA in Q2 2017 and held it in 5 quarters. The position peaked at $101K in Q2 2017. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Two Sigma Securities reported no remaining Iovance Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Two Sigma Securities sold 24,565 Iovance Biotherapeutics shares in Q2 2026, an estimated $86.2K.
  • Two Sigma Securities first reported a position in Iovance Biotherapeutics in Q2 2017 and held it in 5 quarters.
  • Two Sigma Securities's Iovance Biotherapeutics position peaked at $101K in Q2 2017.
  • 293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.